Nalbandian T. A., Antonyan I. M.

IMPACT OF METABOLIC DISORDERS ON THE COURSE OF PROSTATE CANCER

---

Show/Download

About the author:

Nalbandian T. A., Antonyan I. M.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

The article presents the results of a study on the survival of patients with prostate cancer (PCa) depending on the presence of metabolic syndrome or its components. It was established that average survival in the presence of any metabolic disorders was lower than in their absence; however, statistically significant differences were ob served only in cases where metabolic syndrome was present, as defined by NCEP ATP III: (31.60 ± 3.55) months vs (45.06 ± 2.13) months (χ² = 8.882; p = 0.003, according to the Mantel–Cox test), and in the presence of diabetes mel litus: (34.76 ± 4.10) months vs (43.93 ± 2.12) months in its absence (χ² = 4.029; p = 0.045, according to the Mantel Cox test). The effect of abdominal obesity, as defined by NCEP ATP III, on survival approached statistical significance: (34.17 ± 4.44) months vs (43.60 ± 2.06) months (χ² = 3.204; p = 0.073, according to the Mantel–Cox test), as did a decrease in HDL-C levels below 1.0 mmol/L: (35.87 ± 3.32) months vs (44.51 ± 2.25) months (χ² = 3.723; p = 0.054, according to the Mantel–Cox test). The results of the survival analysis in patients with PCa using Cox regression revealed that the negative impact of metabolic syndrome (MS) on three-year survival in PCa was more pronounced in patients under 70 years of age (Exp(B): 0.330 [0.157; 0.695], p = 0.004), while the effect was not significant in patients aged 70 years and older (p = 0.147). In addition, the effect of MS was significant in patients with PCa stages 1–3 according to the ISUP classification (Exp(B): 0.393 [0.180; 0.859], p = 0.019), but not in patients with stages 4–5 (p = 0.661). The obtained results indicate that metabolic disorders negatively affect the course of PCa, leading to reduced patient survival, which must be taken into account when determining treatment strategies.

Tags:

Bibliography:

1. Yefimenko OV, redactor. Rak v Ukrayini, 2021-2022. Zakhvoryuvanist, smertnist, pokaznyky diyalnosti onkolohichnoyi sluzhby. Byuleten Natsionalnoho kantser-reyestru Ukrayiny № 24. Kyyiv: Natsionalnyy kantser-reyestr Ukrayiny; 2023. Dostupno: http://www.ncru.inf.ua/publications/BULL_24. [in Ukrainian].
2. Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 Update on prostate cancer epidemiology and risk factors - a systematic review. Eur Urol. 2023;84(2):191-206. DOI: 10.1016/j.eururo.2023.04.021.
3. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. DOI: 10.3322/caac.21763.
4.  Derzhavnyy ekspertnyy tsentr MOZ Ukrayiny. Klinichna nastanova zasnovana na dokazakh Rak peredmikhurovoyi zalozy. Kyyiv: DETS MOZ Ukrayiny, Natsionalnyy instytut raku; 2023. 288 s. Dostupno: https://www.dec.gov.ua/mtd/rak-peredmihurovoyi-zalozy. [in Ukrainian].
5.  Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol.2024;86(2):148-163. DOI: 10.1016/j.eururo.2024.03.027.
6.  Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(10):1067-1096. DOI: 10.6004/jnccn.2023.0050.
7. Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2024;86(2):164-182. DOI: 10.1016/j.eururo.2024.04.010.
8.  Berchuck JE, Viscuse PV, Beltran H, Aparicio A. Clinical considerations for the management of androgen indifferent prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):623-637. DOI: 10.1038/s41391-021-00332-5.
9.  Kimura T, Sato S, Takahashi H, Egawa S. Global Trends of Latent Prostate Cancer in Autopsy Studies. Cancers (Basel). 2021;13(2):359. DOI: 10.3390/cancers13020359.
10.  Alemany M. The Metabolic Syndrome, a Human Disease. Int J Mol Sci. 2024;25(4):2251. DOI: 10.3390/ijms25042251.
11. Harborg S, Kjærgaard KA, Thomsen RW, Borgquist S, Cronin-Fenton D, Hjorth CF. New horizons: epidemiology of obesity, diabetes mellitus, and cancer prognosis. J Clin Endocrinol Metab. 2024;109(4):924-935. DOI: 10.1210/clinem/dgad450.
12.  Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management. Cancers (Basel). 2023;15(2):485. DOI: 10.3390/cancers15020485.
13.  Tymoshenko AV. Osoblyvosti vplyvu metabolichnoho syndromu na ahresyvnist perebihu raku peredmikhurovoyi zalozy. Klinichna onkolohiya. 2023;13(2):123-126. Dostupno: http://nbuv.gov.ua/UJRN/klinonk_2023_13 _2_11. [in Ukrainian].
14.  Cheng S, Zheng Q, Ding G, Li G. Influence of serum total cholesterol, LDL, HDL, and triglyceride on prostate cancer recurrence after radical prostatectomy. Cancer Manag Res. 2019;11:6651-6661. DOI: 10.2147/CMAR.S204947.
15.  Guerrios-Rivera L, Howard LE, Wiggins EK, Hoyo C, Grant DJ, Erickson TR, et al. Metabolic syndrome is associated with aggressive prostate cancer regardless of race. Cancer Causes Control. 2023;34(3):213-221. DOI: 10.1007/s10552-022-01649-9.
16.  Lebdai S, Mathieu R, Leger J, Haillot O, Vincendeau S, Rioux-Leclercq N, et al. Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy. Urol Oncol. 2018;36(2):80.e17-80.e24. DOI: 10.1016/j.urolonc.2017.09.026.
17.  Neshat S, Rezaei A, Farid A, Sarallah R, Javanshir S, Ahmadian S. The tangled web of dyslipidemia and cancer: Is there any association? J Res Med Sci. 2022;27:93. DOI: 10.4103/jrms.jrms_267_22.
18.  WHO. Obesity and Overweight. Geneva: World Health Organization; 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
19.  Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet. 2005;366(9491):1059-62. DOI: 10.1016/S0140-6736(05)67402-8.
20.  Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007;30(1):8-13. DOI: 10.2337/dc06-1414.
21.  Colicchia M, Morlacco A, Rangel LJ, Carlson RE, Dal Moro F, Karnes RJ. Role of metabolic syndrome on perioperative and oncological outcomes at radical prostatectomy in a low-risk prostate cancer cohort potentially eligible for active surveillance. Eur Urol Focus. 2019;5(3):425-432. DOI: 10.1016/j.euf.2017.12.005.
22.  An H, Ma D, Mei Y, Wang L, Maimaitiyiming A, Zhuo T, et al. Metabolic syndrome and metastatic prostate cancer correlation study, a real world study in a prostate cancer clinical research center, Xinjiang, China. Front Endocrinol (Lausanne). 2022;13:1090763. DOI: 10.3389/fendo.2022.1090763.
23.  Crawley D, Chamberlain F, Garmo H, Rudman S, Zethelius B, Holmberg L, et al. A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus. Ecancermedicalscience. 2018;12:802. DOI: 10.3332/ecancer.2018.802.
24.  Lee J, Giovannucci E, Jeon JY. Diabetes and mortality in patients with prostate cancer: a meta-analysis. Springerplus. 2016;5(1):1548. DOI: 10.1186/s40064-016-3233-y.
25.  Zhou P, Li B, Liu B, Chen T, Xiao J. Prognostic role of serum total cholesterol and high-density lipoprotein cholesterol in cancer survivors: A systematic review and meta-analysis. Clin Chim Acta. 2018;477:94-104. DOI: 10.1016/j.cca.2017.11.039.
26.  Blanc-Lapierre A, Spence A, Karakiewicz PI, Aprikian A, Saad F, Parent MÉ. Metabolic syndrome and prostate cancer risk in a population based case-control study in Montreal, Canada. BMC Public Health. 2015;15:913. DOI: 10.1186/s12889-015-2260-x.
27.  Kelkar S, Oyekunle T, Eisenberg A, Howard L, Aronson WJ, Kane CJ, et al. Diabetes and prostate cancer outcomes in obese and nonobese men after radical prostatectomy. JNCI Cancer Spectr. 2021;5(3):pkab023. DOI: 10.1093/jncics/pkab023.
28.  Arthur R, Møller H, Garmo H, Häggström C, Holmberg L, Stattin P, et al. Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study. Cancer Causes Control. 2019;30(2):195-206. DOI: 10.1007/s10552-018-1093-1.

Publication of the article:

«Bulletin of problems biology and medicine», Issue 2,177, 224-232 pages, index UDC 616.65-006:616-008

DOI:

10.29254/2077-4214-2025-2-177-224-232